한글목차

약제 요약

HTD1801(베르베린 우르소데옥시콜산 또는 BUDCA)은 베르베린과 우르소데옥시콜산의 이온성 염으로, NASH 및 일부 합병증에 대한 1회 치료로 병용 치료의 가능성을 제공하는 분자체입니다. 추정되는 환자에서 광범위한 대사 활성을 가진 단일 분자입니다. 경구 투여가 가능하며 비교적 잘 견딜 수 있습니다.

2상 무작위 대조군 연구 데이터는 당뇨병 및 기타 대사증후군을 동반한 환자에서 NASH 치료제로서 BUDCA의 추가 개발을 지지하며, 향후 임상시험에서 간 지방량(LFC) 감소가 병리조직학적 개선과 상관관계가 있을 것으로 예측됩니다. 예측됩니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 비알코올성 지방성 간염(NASH)용 HTD1801에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 비알코올성 지방간염(NASH)에서 HTD1801의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 HTD1801 시장 평가

• 비알코올성 지방간염(NASH)에서 HTD1801 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 비알코올성 지방간염(NASH)용 HTD1801 시장 규모
• 시장의 분석 : 국가별
  • 미국의 비알코올성 지방간염(NASH)용 HTD1801 시장 규모
  • 독일의 비알코올성 지방간염(NASH)용 HTD1801 시장 규모
  • 영국의 비알코올성 지방간염(NASH)용 HTD1801 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"HTD1801 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about HTD1801 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the HTD1801 for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the HTD1801 for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HTD1801 market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

HTD1801 (berberine ursodeoxycholate or BUDCA) is an ionic salt of berberine and ursodeoxycholic acid, representing a molecular entity that offers the possibility of combination therapy for NASH and some of its comorbidities in a single treatment. BUDCA is a single molecule with a broad spectrum of metabolic activity in patients with fatty liver disease and presumed NASH. It is orally administered and relatively well tolerated.

The data from the Phase II randomized controlled trial support further development of BUDCA as a treatment for NASH in patients with diabetes and other features of the metabolic syndrome, and it is anticipated that the reduction in liver fat content (LFC) will correlate with histopathologic improvement in future studies.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the HTD1801 description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on HTD1801 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HTD1801 research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around HTD1801.
• The report contains forecasted sales of HTD1801 for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for HTD1801 in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HTD1801 Analytical Perspective by DelveInsight

• In-depth HTD1801 Market Assessment

This report provides a detailed market assessment of HTD1801 for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• HTD1801 Clinical Assessment

The report provides the clinical trials information of HTD1801 for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HTD1801 dominance.
• Other emerging products for NASH are expected to give tough market competition to HTD1801 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HTD1801 in NASH.
• Our in-depth analysis of the forecasted sales data of HTD1801 from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HTD1801 in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of HTD1801?
• What is the clinical trial status of the study related to HTD1801 in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HTD1801 development?
• What are the key designations that have been granted to HTD1801 for NASH?
• What is the forecasted market scenario of HTD1801 for NASH?
• What are the forecasted sales of HTD1801 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to HTD1801 for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. HTD1801 Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. HTD1801 Market Assessment

• 5.1. Market Outlook of HTD1801 in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of HTD1801 in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of HTD1801 in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of HTD1801 in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of HTD1801 in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of HTD1801 in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of HTD1801 in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of HTD1801 in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of HTD1801 in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options